Following Through On Breakthrough: What’s Next For FDASIA Success?
This article was originally published in RPM Report
Executive Summary
FDA is building a case for enhanced funding to support the “Breakthrough” therapy program and at the same time is working to educate sponsors on how to use the new program effectively. The 21st Century Cures process floated a proposal for a new “Breakthrough” approval pathway – though that idea has been dropped. Still, it sets up an interesting discussion heading into 2017.
You may also be interested in...
First Draft FDA User Fee Bill Is Squeaky Clean
House and Senate release discussion draft of user fee reauthorization legislation that does not include any additional policy or practice changes for US FDA, though they may arrive later.
First Draft FDA User Fee Bill Is Squeaky Clean
House and Senate release discussion draft of user fee reauthorization legislation that does not include any additional policy or practice changes for US FDA, though they may arrive later.
FDA's Breakthrough Workload Will Be Eased By Hiring Reviewers With PDUFA VI Funds
User fees won't support dedicated staff, but rather FTEs that will work on the popular program as needed.